- Home
- NKTR vs FULC Comparison
NKTR vs FULC Comparison
Compare NKTR & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NKTR | FULC |
|---|---|---|
| Founded | 1990 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 718.4M |
| IPO Year | 1996 | 2019 |
Fundamental Metrics
Financial Performance| Metric | NKTR | FULC |
|---|---|---|
| Price | $75.00 | $7.47 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $142.00 | $16.38 |
| AVG Volume (30 Days) | 825.7K | ★ 1.1M |
| Earning Date | 06-10-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $307,711,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 86.00 | N/A |
| 52 Week Low | $0.43 | $2.32 |
| 52 Week High | $77.00 | $15.74 |
Technical Indicators
Market Signals| Indicator | NKTR | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 65.32 | 33.05 |
| Support Level | $52.99 | $7.40 |
| Resistance Level | $75.44 | $8.17 |
| Average True Range (ATR) | 3.99 | 0.51 |
| MACD | -0.64 | -0.06 |
| Stochastic Oscillator | 84.72 | 9.87 |
Price Performance
Historical ComparisonAbout NKTR Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.